Skip to main content
. 2022 Aug 21;28(31):4310–4327. doi: 10.3748/wjg.v28.i31.4310

Table 5.

Biomarkers (glypican-1-positive circulating exosomes and carbohydrate antigen 19-9) profiles in the study groups, n = 88

Biomarker
MCL, n = 40
HR, n = 20
NLOD, n = 20
CG, n = 8
Total, n = 88
P value
GPC1+ crExos, % < 0.001
Median 99.4 82.0 12.6 16.2 86.8
Min/Max 6.4/99.9 1.1/99.0 2.1/93.9 1.2/24.5 1.1/99.9
IQR 94.9-99.8 28.9-98.2 5.2-63.4 6.6-20.1 18.6-99.4
CA 19-9 in U/mL NS
Median 20.4 16.9 18.8 30.6 18.4
Min/Max 8.5/206.6 8.3/28.0 12.8-48.7 13.7-69.6 8.3/206.6
IQR 14.0-35.8 11.7-18.1 16.6-23.4 15.0-40.8 14.2-27.7

P value for Kruskal-Wallis test. CA 19-9: Carbohydrate antigen 19-9; CG: Control group; HR: Hereditary risk; IQR: Interquartile range; GPC1+ crExos: Glypican-1 positive circulating exosomes; Max: Maximum; MCL: Mucinous cystic lesion; Min: Minimum; NLOD: New-late onset diabetes mellitus; NS: Non-significant.

HHS Vulnerability Disclosure